Travere Therapeutics, Inc. - Common Stock (TVTX)

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Shares shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug.

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

The company has made a name for itself with a drug that treats a progressive kidney condition.

Travere Therapeutics (TVTX) reported strong Q2 2025 results, beating revenue and earnings estimates, driven by FILSPARI sales and milestone payments. Shares rose 2.3% post-earnings.

Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026.

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.